Publicis reveals diversity data and outlines 7 actions to improve equality
An internal memo was sent to staff today.
News
California posts $6m tobacco control RFP
The state expects to make a decision later this summer.
Join MM&M Move Together, a fitness challenge for charity this August
Register for this MM&M event from August 24-28, 2020 to take care of your mental and physical health.
Five things for pharma marketers to know: Wednesday, July 1, 2020
FDA outlines conditions to approve coronavirus vaccine; Fauci warns daily COVID-19 cases could more than double in U.S.; Join the MM&M Move Together event.
Five things for pharma marketers to know: Tuesday, June 30, 2020
Gilead announces price for remdesivir; Bipartisan support of drug price legislation has waned; More states slow down reopening as COVID-19 cases rise.
Gilead names remdesivir price
The treatment will cost $3,120 for a five-day treatment course for a patient with private insurance in the U.S.
Five things for pharma marketers to know: Monday, June 29, 2020
Justice Department asks Supreme Court to overturn ACA; States reverse reopening as virus cases climb; Submit creative to MM&M’s #CreateHealthEquity initiative.
Point of care and the pandemic
The inside story of how one of healthcare marketing’s most important channels navigated COVID-19 – and may have emerged stronger and smarter.
Pharma brands tweak media mix to align with their stance on racism
As drug makers mull whether to join a July ad boycott against Facebook, will #BLM prove a tipping point for health brands’ new social activism?
Five things for pharma marketers to know: Friday, June 26, 2020
CDC changes populations at risk for severe COVID-19 illness; Texas pauses reopening as cases spike; CDC considers TikTok to educate young people about virus.
Want to read more?
Please login or register first to view this content.
